Table E6.

Hospitalization risk comparing patients with an AEC greater than 0.15 × 10³/μL versus those with an AEC less than 0.15 × 10³/μL

Time between AEC test date and SARS-CoV-2 test date	n	All patients		Chronic obstructive pulmonary disease		Asthma
		No ICS	ICS	No ICS	ICS	No ICS	ICS
<2 y∗	24,095	0.97 (0.90-1.03)	0.85 (0.75-0.97)	1.05 (0.82-1.33)	0.79 (0.64-0.98)	0.89 (0.73-1.10)	0.78 (0.65-0.93)
<1 y†	15,058	0.93 (0.86-1.00)	0.81 (0.70-0.95)	1.17 (0.89-1.54)	0.77 (0.61-0.98)	0.93 (0.73-1.18)	0.76 (0.62-0.94)

AEC, absolute eosinophil count; ICS, inhaled corticosteroids; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

The analysis was stratified by the time between the AEC test date and the severe acute respiratory syndrome coronavirus 2 test date inhaled corticosteroids therapy and airway disease category.

Effect of a high blood absolute eosinophil count greater than 0.15 × 10³ cells/μL on hospital outcomes is estimated by weighting each patient with the inverse propensity score and controlling for the propensity score as a covariate in the model. Medications include nonsteroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, ICS, intranasal corticosteroids, and immunosuppressive therapy (that includes systemic corticosteroids). Comorbidities include asthma, chronic obstructive pulmonary disease/emphysema, diabetes, hypertension, coronary artery disease, heart failure and cancer (historical or current), immunosuppressive disease, and connective tissue disease.

^∗Patients for whom AEC measurements were obtained within 2 years (median [interquartile range]: 291 [126-457] days) of the SARS-CoV-2 test date.

^†Patients for whom AEC measurements were obtained within 1 year (median [interquartile range]: 173 [55-275] days) of the SARS-CoV-2 test date.